High-throughput screening of Sirtuin family of genes in breast cancer

Gene

Volumn 586, Issue 1, 2016, Pages 123-128

  Igci, Mehri ^a   Kalender, Mehmet Emin ^a   Borazan, Ersin ^a   Bozgeyik, Ibrahim ^b   Bayraktar, Recep ^a   Bozgeyik, Esra ^a   Camci, Celaletdin ^a   Arslan, Ahmet ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Cancer cells; Expression; SIRT; SIRT1; Sirtuins

Indexed keywords

RNA; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC ANALYZER; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MCF 7 CELL LINE; MIDDLE AGED; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKBR3 CELL LINE; UPREGULATION; BREAST TUMOR; GENE EXPRESSION; GENETICS; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SIRTUINS;

EID: 84964961749     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.04.023     Document Type: Article

References (38)

1. Alhazzazi T.Y., Kamarajan P., Joo N., Huang J.Y., Verdin E., D'Silva N.J., Kapila Y.L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117:1670-1678.
2. Ashraf N., Zino S., MacIntyre A., Kingsmore D., Payne A.P., George W.D., Shiels P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 2006, 95:1056-1061.
3. Chen W.Y., Wang D.H., Yen R.W.C., Luo J.Y., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
4. Csibi A., Fendt S.M., Li C., Poulogiannis G., Choo A.Y., Chapski D.J., Jeong S.M., Dempsey J.M., Parkhitko A., Morrison T., Henske E.P., Haigis M.C., Cantley L.C., Stephanopoulos G., Yu J., Blenis J. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153:840-854.
5. Dan L., Klimenkova O., Klimiankou M., Klusman J.H., van den Heuvel-Eibrink M.M., Reinhardt D., Welte K., Skokowa J. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Hematol. J. 2012, 97:551-559.
6. De Nigris F., Cerutti J., Morelli C., Califano D., Chiariotti L., Viglietto G., Santelli G., Fusco A. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br. J. Cancer 2002, 87:1479.
7. Eades G., Yao Y., Yang M.H., Zhang Y.S., Chumsri S., Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem. 2011, 286:25992-26002.
8. Ergun S., Ulasli M., Igci Y.Z., Igci M., Kirkbes S., Borazan E., Balik A., Yumrutas O., Camci C., Cakmak E.A., Arslan A., Oztuzcu S. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol. Biol. Rep. 2015, 42:497-505.
9. Ergun S., Tayeb T.S., Arslan A., Temiz E., Arman K., Safdar M., Dagli H., Korkmaz M., Nacarkahya G., Kirkbes S., Oztuzcu S. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Gene 2015, 555:377-381.
10. Finley L.W., Carracedo A., Lee J., Souza A., Egia A., Zhang J., Teruya-Feldstein J., Moreira P.I., Cardoso S.M., Clish C.B., Pandolfi P.P., Haigis M.C. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011, 19:416-428.
11. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., Hahn W.C., Guarente L.P., Sinclair D.A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008, 3.
12. He X., Nie H., Hong Y., Sheng C., Xia W., Ying W. SIRT2 activity is required for the survival of c6 glioma cells. Biochem. Biophys. Res. Commun. 2012, 417:468-472.
13. Herranz D., Munoz-Martin M., Canamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., Serrano M. SIRT1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
14. Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y., Kamitani H., Watanabe T., Ohama E., Tahimic C.G., Kurimasa A., Oshimura M. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun. 2003, 309:558-566.
15. Holloway K.R., Barbieri A., Malyarchuk S., Saxena M., Nedeljkovic-Kurepa A., Mehl M.C., Wang A., Gu X., Pruitt K. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol. Endocrinol. 2013, 27:480-490.
16. Jang S.H., Min K.W., Paik S.S., Jang K.S. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J. Clin. Pathol. 2012, 65:735-739.
17. Jeong S.M., Xiao C., Finley L.W., Lahusen T., Souza A.L., Pierce K., Li Y.H., Wang X., Laurent G., German N.J., Xu X., Li C., Wang R.H., Lee J., Csibi A., Cerione R., Blenis J., Clish C.B., Kimmelman A., Deng C.X., Haigis M.C. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23:450-463.
18. Khongkow M., Olmos Y., Gong C., Gomes A.R., Monteiro L.J., Yague E., Cavaco T.B., Khongkow P., Man E.P., Laohasinnarong S., Koo C.Y., Harada-Shoji N., Tsang J.W., Coombes R.C., Schwer B., Khoo U.S., Lam E.W. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 2013, 34:1476-1486.
19. Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X.L., Li C.L., Veenstra T.D., Li B., Yu H.T., Ji J.F., Wang X.W., Park S.H., Cha Y.I., Gius D., Deng C.X. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011, 20:487-499.
20. Kiran S., Oddi V., Ramakrishna G. Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response. Exp. Cell Res. 2015, 331:123-141.
21. Lai C.C., Lin P.M., Lin S.F., Hsu C.H., Lin H.C., Hu M.L., Hsu C.M., Yang M.Y. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013, 34:1847-1854.
22. Lee H., Kim K.R., Noh S.J., Park H.S., Kwon K.S., Park B.H., Jung S.H., Youn H.J., Lee B.K., Chung M.J., Koh D.H., Moon W.S., Jang K.Y. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum. Pathol. 2011, 42:204-213.
23. Li Y., Matsumori H., Nakayama Y., Osaki M., Kojima H., Kurimasa A., Ito H., Mori S., Katoh M., Oshimura M., Inoue T. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011, 16:34-45.
24. Liu P.Y., Xu N., Malyukova A., Scarlett C.J., Sun Y.T., Zhang X.D., Ling D., Su S.P., Nelson C., Chang D.K., Koach J., Tee A.E., Haber M., Norris M.D., Toon C., Rooman I., Xue C., Cheung B.B., Kumar S., Marshall G.M., Biankin A.V., Liu T. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2013, 20:503-514.
25. Lu W., Zuo Y., Feng Y., Zhang M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol. 2014, 35:10699-10705.
26. Noguchi A., Li X.H., Kubota A., Kikuchi K., Kameda Y., Zheng H.C., Miyagi Y., Aoki I., Takano Y. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2013, 115:385-392.
27. Peters C.J., Rees J.R., Hardwick R.H., Hardwick J.S., Vowler S.L., Ong C.A., Zhang C., Save V., O'Donovan M., Rassl D., Alderson D., Caldas C., Fitzgerald R.C. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010, 139:1995-2004.
28. Roth M., Chen W. Sorting out functions of sirtuins in cancer. Oncogene 2014, 33:1609-1620.
29. Simic P., Williams E.O., Bell E.L., Gong J.J., Bonkowski M., Guarente L. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 2013, 3:1175-1186.
30. Wang J.C., Kafeel M.I., Avezbakiyev B., Chen C., Sun Y., Rathnasabapathy C., Kalavar M., He Z., Burton J., Lichter S. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81:325-329.
31. Wu M., Wei W., Xiao X., Guo J., Xie X., Li L., Kong Y., Lv N., Jia W., Zhang Y. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med. Oncol. 2012, 29:3240-3249.
32. Yu E.J., Kim S.H., Heo K., Ou C.Y., Stallcup M.R., Kim J.H. Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor alpha activity and co-activator synergy. Nucleic Acids Res. 2011, 39:6932-6943.
33. Yuan H., Su L., Chen W.Y. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013, 6:1399.
34. Yumrutas O., Oztuzcu S., Buyukhatipoglu H., Bozgeyik I., Bozgeyik E., Igci Y.Z., Bagis H., Cevik M.O., Kalender M.E., Eslik Z., Arslan A. The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. Tumour Biol. 2015, 36:4427-4432.
35. Zhang Y.Y., Zhou L.M. SIRT3 inhibits hepatocellular carcinoma cell growth through reducing MDM2-mediated p53 degradation. Biochem. Biophys. Res. Commun. 2012, 423:26-31.
36. Zhang Y., Zhang M., Dong H., Yong S., Li X., Olashaw N., Kruk P.A., Cheng J.Q., Bai W., Chen J., Nicosia S.V., Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009, 28:445-460.
37. Zhang C.Z., Liu L., Cai M., Pan Y., Fu J., Cao Y., Yun J. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 2012, 7.
38. Zuo Q.Q., Wu W.J., Li X., Zhao L., Chen W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol. Rep. 2012, 27:819-824.